secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-08-12T11:28:40+00:00
Accession:  0001104659-26-094466
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Q2 2026 net loss $28.6M; CARDAMYST coverage jumps to ~50% of commercial lives
--------------------------------------------------------------------------------

- Q2 2026 net loss of $28.6M ($0.21/share) vs $13.0M ($0.20/share) in Q2 2025.
- Product revenue $0.6M in Q2; first sales from CARDAMYST launched mid-Feb 2026.
- Cash, equivalents, short-term investments $170.6M as of June 30, 2026; runway into H2 2027.
- CARDAMYST: >800 prescribers, >1,500 scripts filled; commercial coverage now ~50% via UnitedHealthcare.
- Phase 3 ReVeRA-301 AFib-RVR trial sites activated; EMA decision on etripamil for PSVT expected H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/0001104659-26-094466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer